Cg Oncology, Inc. CGON
We take great care to ensure that the data presented and summarized in this overview for CG Oncology, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CGON
Top Purchases
Top Sells
About CGON
Insider Transactions at CGON
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 29
2024
|
Hong Fang Song |
SELL
Open market or private sale
|
Indirect |
650,455
-23.85%
|
$22,765,925
$35.36 P/Share
|
|
Jan 29
2024
|
Hong Fang Song |
BUY
Open market or private purchase
|
Direct |
263,157
+30.0%
|
$4,999,983
$19.0 P/Share
|
|
Jan 29
2024
|
Hong Fang Song |
BUY
Conversion of derivative security
|
Indirect |
4,941,368
+50.0%
|
-
|
|
Jan 29
2024
|
Hong Fang Song |
BUY
Conversion of derivative security
|
Direct |
350,771
+50.0%
|
-
|
|
Jan 29
2024
|
Corleen M. Roche CFO |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$38,000
$19.0 P/Share
|
|
Jan 29
2024
|
Vijay Kasturi Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,315
+50.0%
|
$24,985
$19.0 P/Share
|
|
Jan 29
2024
|
Decheng Capital Global Life Sciences Fund Iv, L.P. |
BUY
Open market or private purchase
|
Indirect |
400,000
+50.0%
|
$7,600,000
$19.0 P/Share
|
|
Jan 29
2024
|
Decheng Capital Global Life Sciences Fund Iv, L.P. |
BUY
Conversion of derivative security
|
Direct |
3,628,198
+44.32%
|
-
|
Last 12 Months Summary
Buy / Acquisition
9.59M
Shares
From
6
Insiders
| Open market or private purchase | 666K shares |
|---|---|
| Conversion of derivative security | 8.92M shares |
Sell / Disposition
650K
Shares
From
1
Insiders
| Open market or private sale | 650K shares |
|---|